iScience · 2019 · 16 citations · 44 references
Life SciencesMedicinal ChemistryMolecular BiologyDrug DesignDrug DiscoveryStructural BiologyAmyloid FormationLigand BindingProtein AggregationProtein OligomerizationProtein StructureAmyloid Beta AggregationAmyloid Beta PeptidesAmyloid FibrilsAmyloid InhibitionOligomerizationProtein Aggregation InhibitionProtein Aggregation InhibitorsRational Design
Amyloid fibril surfaces can convert soluble proteins into toxic oligomers and are attractive targets for intervention of protein aggregation diseases. Thus far, molecules identified with inhibitory activity are either large proteins or flat cyclic compounds lacking in specificity. The main design difficulty is flatness of amyloid surfaces and the lack of knowledge on binding interfaces. Here, we demonstrate, for the first time, a rational design of alpha-helical peptide inhibitors targeting the amyloid-beta 40 (Aβ40) fibril surfaces, based on our in silico finding that a helical fragment of Aβ40 interacts in a unique way with side-chain arrays on the fibril surface. We strengthen the fragment's binding capability through mutations and helicity enhancement with our Terminal Aspartic acid strategy. The resulting inhibitor shows micromolar affinity for the fibril surface, effectively impedes the surface-mediated oligomerization of Aβ40, and mitigates its cytotoxicity. This work opens up an avenue to designing aggregation modulators for amyloid diseases.
44
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
Maj-Linda B. Selenica, Milene L. Brownlow, Jeffy P. Jimenez et al. · Neurodegenerative Diseases · 2012 · 10.4K citations · Full text
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Sylvain Lesné, Ming Teng Koh, Linda Kotilinek et al. · Nature · 2006 · 2.8K citations